Disseminated Intravascular Coagulation (DIC) Global Market Report 2025

The disseminated intravascular coagulation (DIC) market size has grown strongly in recent years. It will grow from $0.46 billion in 2024 to $0.49 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth during the historic period can be attributed to the increasing prevalence of sepsis, a rise in trauma cases, a growing incidence of cancer, higher healthcare expenditures, improved awareness among healthcare professionals, and the increased adoption of targeted therapies.

The disseminated intravascular coagulation (DIC) market size is expected to see strong growth in the next few years. It will grow to $0.59 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The growth during the forecast period can be attributed to the rising adoption of targeted therapies, increased focus on early disease detection, growing investments in healthcare infrastructure, expansion of clinical research on coagulopathy treatments, and greater awareness of rare hematological conditions. Key trends include advancements in diagnostic assays, adoption of novel anticoagulant therapies, the rise of personalized medicine approaches, integration of AI in diagnostics, improved patient monitoring technologies, and the development of targeted treatments.

The rising incidence of cancer is expected to drive the growth of the disseminated intravascular coagulation (DIC) market. Cancer is a disease characterized by the uncontrolled proliferation and spread of abnormal cells, which can invade and damage normal tissues. The increasing number of cancer cases is attributed to factors such as an aging population, lifestyle changes, environmental exposure, infections, and genetic predisposition. Cancer can lead to disseminated intravascular coagulation (DIC) by excessively activating the coagulation cascade through tumor-produced procoagulant substances, resulting in widespread clotting and bleeding. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that in 2022, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded globally. Projections indicate that these figures could rise to 29.9 million new cases and 15.3 million deaths annually by 2040. As a result, the increasing prevalence of cancer is fueling the growth of the disseminated intravascular coagulation (DIC) market.

Leading companies in the disseminated intravascular coagulation (DIC) market are advancing coagulation diagnostic technologies, such as next-generation blood clotting tests, to improve diagnostic accuracy, speed, and convenience. These innovations enable timely intervention and enhance patient outcomes. Next-generation blood clotting tests are advanced diagnostic tools designed to assess blood coagulation more precisely, efficiently, and comprehensively than traditional methods. For instance, in June 2022, LumiraDx Limited, a UK-based healthcare company, expanded its cardiovascular testing portfolio by obtaining CE Mark approvals for its NT-proBNP and updated D-Dimer tests. These enhancements strengthen the LumiraDx Platform’s ability to assist clinicians in diagnosing heart failure and ruling out venous thromboembolism at the point of care. Such advancements aim to improve the early detection and management of cardiovascular and thrombotic conditions, including disseminated intravascular coagulation (DIC).

In March 2024, MediLink Therapeutics (Suzhou) Co. Ltd., a China-based biotech company, entered into a collaboration with Amgen Inc. to evaluate YL201 for the treatment of thrombotic disorders, including disseminated intravascular coagulation (DIC). This partnership seeks to advance blood clotting therapies, improving treatment effectiveness and patient outcomes. Amgen Inc. is a US-based biopharmaceutical company specializing in the discovery, development, and manufacturing of innovative therapeutics.

Major players in the disseminated intravascular coagulation (DIC) market are Nihon Kohden Corporation, Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis AG, Thermo Fisher Scientific Inc., Fresenius Kabi AG, GlaxoSmithKline plc, Danaher Corporation, Eli Lily and Company, Siemens Healthineers, Teva Pharmaceutical Industries Ltd., Mylan N.V., Grifols S.A., Eisai Co. Ltd., Beckman Coulter Inc., Sysmex Corporation, and Bio-Rad Laboratories Inc.

North America was the largest region in the disseminated intravascular coagulation (DIC) market in 2024. The regions covered in disseminated intravascular coagulation (DIC) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the disseminated intravascular coagulation (DIC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Disseminated intravascular coagulation (DIC) is a severe, life-threatening condition marked by excessive blood clotting, which eventually leads to significant bleeding due to the depletion of clotting factors and platelets. It is triggered by underlying conditions such as sepsis, trauma, malignancies, and obstetric complications.

The primary treatments for disseminated intravascular coagulation (DIC) include medications, transfusions, surgery, and other therapeutic approaches. Medications consist of anticoagulants, blood products, and supportive drugs aimed at managing clotting and bleeding complications related to DIC. Diagnostic methods include a complete blood count with blood smear examination, partial thromboplastin time (PTT), fibrinogen blood test, D-dimer test, and other diagnostic procedures. These tests are administered through various routes, such as oral, parenteral, and alternative methods, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Treatment options are utilized across hospitals, specialty clinics, homecare settings, and other healthcare facilities.

The disseminated intravascular coagulation (DIC) market research report is one of a series of new reports that provides disseminated intravascular coagulation (DIC) market statistics, including the disseminated intravascular coagulation (DIC) industry's global market size, regional shares, competitors with a disseminated intravascular coagulation (DIC) market share, detailed disseminated intravascular coagulation (DIC) market segments, market trends and opportunities, and any further data you may need to thrive in the disseminated intravascular coagulation (DIC) industry. This disseminated intravascular coagulation (DIC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The disseminated intravascular coagulation (DIC) market consists of revenues earned by entities by providing services such as pharmaceutical treatments, anticoagulant therapies, diagnostic services, and critical care interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The disseminated intravascular coagulation (DIC) market also includes sales of diagnostic tools, anticoagulant medications, and blood products such as platelets, fresh frozen plasma, or cryoprecipitate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.